tiprankstipranks
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market
SMMT
Summit Therapeutics
RESEARCH TOOLSreports

Summit Therapeutics (SMMT) Stock Forecast & Price Target

1,873 Followers
See the Price Targets and Ratings of:

SMMT Analyst Ratings

Strong Buy
12Ratings
Strong Buy
10 Buy
2 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Summit
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SMMT Stock 12 Month Forecast

Average Price Target

$33.82
▲(71.94% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $33.82 with a high forecast of $45.00 and a low forecast of $17.00. The average price target represents a 71.94% change from the last price of $19.67.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","46":"$46","21.25":"$21.3","29.5":"$29.5","37.75":"$37.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,21.25,29.5,37.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.92,20.92615384615385,22.932307692307695,24.93846153846154,26.944615384615386,28.950769230769232,30.956923076923076,32.963076923076926,34.96923076923077,36.97538461538461,38.98153846153846,40.987692307692306,42.99384615384615,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.92,20.06615384615385,21.212307692307693,22.35846153846154,23.504615384615384,24.65076923076923,25.79692307692308,26.943076923076923,28.08923076923077,29.235384615384618,30.38153846153846,31.52769230769231,32.673846153846156,{"y":33.82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.92,18.772307692307695,18.624615384615385,18.47692307692308,18.32923076923077,18.181538461538462,18.033846153846156,17.886153846153846,17.73846153846154,17.590769230769233,17.443076923076923,17.295384615384616,17.147692307692306,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.49,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 53, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$33.82Lowest Price Target$17.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on SMMT
Salveen Richter
Goldman Sachs
Goldman Sachs
$41
Buy
108.44%
Upside
Reiterated
04/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on SMMT
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$45
Buy
128.77%
Upside
Initiated
04/08/26
Positioning Ivonescimab to Anchor a ~$200B PD-1xVEGF Market: Early NSCLC Validation and Commercial Head Start Support Buy Rating on Summit
Wells Fargo Analyst forecast on SMMT
Mohit Bansal
Wells Fargo
Wells Fargo
$30
Buy
52.52%
Upside
Assigned
04/02/26
Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
Barclays Analyst forecast on SMMT
Etzer Darout
Barclays
Barclays
$18
Hold
-8.49%
Downside
Reiterated
03/30/26
Barclays Remains a Hold on Summit Therapeutics (SMMT)
Citi Analyst forecast on SMMT
Yigal Nochomovitz
Citi
Citi
$40
Buy
103.36%
Upside
Reiterated
03/20/26
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)
H.C. Wainwright Analyst forecast on SMMT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$30
Buy
52.52%
Upside
Reiterated
03/02/26
H.C. Wainwright Sticks to Its Buy Rating for Summit Therapeutics (SMMT)
TD Cowen Analyst forecast on SMMT
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/24/26
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (NASDAQ: BLFS), Alkermes (NASDAQ: ALKS) and Summit Therapeutics (NASDAQ: SMMT)
Evercore ISI Analyst forecast on SMMT
Cory Kasimov
Evercore ISI
Evercore ISI
$34
Buy
72.85%
Upside
Reiterated
02/24/26
Summit Therapeutics (SMMT) Receives a Buy from Evercore ISI
Piper Sandler Analyst forecast on SMMT
Kelsey Goodwin
Piper Sandler
Piper Sandler
$17
Hold
-13.57%
Downside
Reiterated
02/24/26
Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT)
Guggenheim Analyst forecast on SMMT
Bradley Canino
Guggenheim
Guggenheim
$40
Buy
103.36%
Upside
Reiterated
02/24/26
Analysts Are Bullish on Top Healthcare Stocks: ADC Therapeutics (ADCT), Addus Homecare (ADUS)
Truist Financial Analyst forecast on SMMT
Asthika Goonewardene
Truist Financial
Truist Financial
$35
Buy
77.94%
Upside
Reiterated
02/24/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (NYSE: HUM), Summit Therapeutics (NASDAQ: SMMT) and Intuitive Surgical (NASDAQ: ISRG)
Jefferies Analyst forecast on SMMT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$42
Buy
113.52%
Upside
Reiterated
01/15/26
Jefferies Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
Wolfe Research Analyst forecast on SMMT
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
―
Hold
―
Initiated
11/17/25
Summit Therapeutics initiated with a Peer Perform at Wolfe ResearchSummit Therapeutics initiated with a Peer Perform at Wolfe Research
Clear Street Analyst forecast on SMMT
William Maughan
Clear Street
Clear Street
$32
Buy
62.68%
Upside
Reiterated
11/10/25
Clear Street Remains a Buy on Summit Therapeutics (SMMT)
UBS Analyst forecast on SMMT
David Dai
UBS
UBS
$30→$33
Buy
67.77%
Upside
Reiterated
11/10/25
Summit Therapeutics (SMMT) Gets a Buy from UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on SMMT
Salveen Richter
Goldman Sachs
Goldman Sachs
$41
Buy
108.44%
Upside
Reiterated
04/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on SMMT
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$45
Buy
128.77%
Upside
Initiated
04/08/26
Positioning Ivonescimab to Anchor a ~$200B PD-1xVEGF Market: Early NSCLC Validation and Commercial Head Start Support Buy Rating on Summit
Wells Fargo Analyst forecast on SMMT
Mohit Bansal
Wells Fargo
Wells Fargo
$30
Buy
52.52%
Upside
Assigned
04/02/26
Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
Barclays Analyst forecast on SMMT
Etzer Darout
Barclays
Barclays
$18
Hold
-8.49%
Downside
Reiterated
03/30/26
Barclays Remains a Hold on Summit Therapeutics (SMMT)
Citi Analyst forecast on SMMT
Yigal Nochomovitz
Citi
Citi
$40
Buy
103.36%
Upside
Reiterated
03/20/26
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)
H.C. Wainwright Analyst forecast on SMMT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$30
Buy
52.52%
Upside
Reiterated
03/02/26
H.C. Wainwright Sticks to Its Buy Rating for Summit Therapeutics (SMMT)
TD Cowen Analyst forecast on SMMT
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/24/26
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (NASDAQ: BLFS), Alkermes (NASDAQ: ALKS) and Summit Therapeutics (NASDAQ: SMMT)
Evercore ISI Analyst forecast on SMMT
Cory Kasimov
Evercore ISI
Evercore ISI
$34
Buy
72.85%
Upside
Reiterated
02/24/26
Summit Therapeutics (SMMT) Receives a Buy from Evercore ISI
Piper Sandler Analyst forecast on SMMT
Kelsey Goodwin
Piper Sandler
Piper Sandler
$17
Hold
-13.57%
Downside
Reiterated
02/24/26
Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT)
Guggenheim Analyst forecast on SMMT
Bradley Canino
Guggenheim
Guggenheim
$40
Buy
103.36%
Upside
Reiterated
02/24/26
Analysts Are Bullish on Top Healthcare Stocks: ADC Therapeutics (ADCT), Addus Homecare (ADUS)
Truist Financial Analyst forecast on SMMT
Asthika Goonewardene
Truist Financial
Truist Financial
$35
Buy
77.94%
Upside
Reiterated
02/24/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (NYSE: HUM), Summit Therapeutics (NASDAQ: SMMT) and Intuitive Surgical (NASDAQ: ISRG)
Jefferies Analyst forecast on SMMT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$42
Buy
113.52%
Upside
Reiterated
01/15/26
Jefferies Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
Wolfe Research Analyst forecast on SMMT
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
―
Hold
―
Initiated
11/17/25
Summit Therapeutics initiated with a Peer Perform at Wolfe ResearchSummit Therapeutics initiated with a Peer Perform at Wolfe Research
Clear Street Analyst forecast on SMMT
William Maughan
Clear Street
Clear Street
$32
Buy
62.68%
Upside
Reiterated
11/10/25
Clear Street Remains a Buy on Summit Therapeutics (SMMT)
UBS Analyst forecast on SMMT
David Dai
UBS
UBS
$30→$33
Buy
67.77%
Upside
Reiterated
11/10/25
Summit Therapeutics (SMMT) Gets a Buy from UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Summit Therapeutics

3 Months
xxx
Success Rate
5/7 ratings generated profit
71%
Average Return
+8.59%
reiterated a xxx
 rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +8.59% per trade.
1 Year
Bradley CaninoGuggenheim
Success Rate
5/8 ratings generated profit
63%
Average Return
+200.99%
reiterated a buy rating 2 months ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +200.99% per trade.
2 Years
xxx
Success Rate
4/8 ratings generated profit
50%
Average Return
+118.46%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +118.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SMMT Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
10
5
10
11
12
Buy
8
5
4
4
2
Hold
4
16
42
48
53
Sell
1
0
0
0
0
Strong Sell
1
0
0
0
0
total
24
26
56
63
67
In the current month, SMMT has received 14 Buy Ratings, 53 Hold Ratings, and 0 Sell Ratings. SMMT average Analyst price target in the past 3 months is 33.82.
Each month's total comprises the sum of three months' worth of ratings.

SMMT Financial Forecast

SMMT Earnings Forecast

Next quarter’s earnings estimate for SMMT is -$0.28 with a range of -$0.40 to -$0.13. The previous quarter’s EPS was -$0.29. SMMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.
Next quarter’s earnings estimate for SMMT is -$0.28 with a range of -$0.40 to -$0.13. The previous quarter’s EPS was -$0.29. SMMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Sales Forecast

Next quarter’s sales forecast for SMMT is $990.00K with a range of $0.00 to $11.17M. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.
Next quarter’s sales forecast for SMMT is $990.00K with a range of $0.00 to $11.17M. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Stock Forecast FAQ

What is SMMT’s average 12-month price target, according to analysts?
Based on analyst ratings, Summit Therapeutics’s 12-month average price target is 33.82.
    What is SMMT’s upside potential, based on the analysts’ average price target?
    Summit Therapeutics has 71.94% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SMMT a Buy, Sell or Hold?
          Summit Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Summit Therapeutics’s price target?
            The average price target for Summit Therapeutics is 33.82. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $17.00. The average price target represents 71.94% Increase from the current price of $19.67.
              What do analysts say about Summit Therapeutics?
              Summit Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of SMMT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.